Literature DB >> 21844912

Targeted therapies: An important piece of the localized prostate cancer puzzle?

James W Denham.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21844912     DOI： 10.1038/nrclinonc.2011.128

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Radiotherapy and short-term androgen deprivation for localized prostate cancer.

Authors:  Christopher U Jones; Daniel Hunt; David G McGowan; Mahul B Amin; Michael P Chetner; Deborah W Bruner; Mark H Leibenhaut; Siraj M Husain; Marvin Rotman; Luis Souhami; Howard M Sandler; William U Shipley
Journal:  N Engl J Med       Date:  2011-07-14       Impact factor: 91.245

2.  Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.

Authors:  James W Denham; Allison Steigler; David S Lamb; David Joseph; Sandra Turner; John Matthews; Chris Atkinson; John North; David Christie; Nigel A Spry; Keen-Hun Tai; Chris Wynne; Catherine D'Este
Journal:  Lancet Oncol       Date:  2011-05       Impact factor: 41.316

3.  Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31.

Authors:  M V Pilepich; R Caplan; R W Byhardt; C A Lawton; M J Gallagher; J B Mesic; G E Hanks; C T Coughlin; A Porter; W U Shipley; D Grignon
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

4.  Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.

Authors:  M V Pilepich; K Winter; M J John; J B Mesic; W Sause; P Rubin; C Lawton; M Machtay; D Grignon
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-08-01       Impact factor: 7.038

5.  A randomized trial (Irish clinical oncology research group 97-01) comparing short versus protracted neoadjuvant hormonal therapy before radiotherapy for localized prostate cancer.

Authors:  John G Armstrong; Charles M Gillham; Mary T Dunne; David A Fitzpatrick; Marie A Finn; Mairín E Cannon; Judy C Taylor; Carmel M O'Shea; Steven J Buckney; Pierre G Thirion
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-08-25       Impact factor: 7.038

Review 6.  Treating prostate cancer with radiotherapy.

Authors:  Anna Wilkins; Chris Parker
Journal:  Nat Rev Clin Oncol       Date:  2010-08-17       Impact factor: 66.675

7.  Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer.

Authors:  Juanita Crook; Charles Ludgate; Shawn Malone; Gad Perry; Libni Eapen; Julie Bowen; Susan Robertson; Gina Lockwood
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-08-15       Impact factor: 7.038

8.  Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial.

Authors:  Anthony V D'Amico; Ming-Hui Chen; Andrew A Renshaw; Marian Loffredo; Philip W Kantoff
Journal:  JAMA       Date:  2008-01-23       Impact factor: 56.272

9.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

Authors:  A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein
Journal:  JAMA       Date:  1998-09-16       Impact factor: 56.272
  9 in total
  1 in total

1.  Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer.

Authors:  Danielle Crawley; Ashish Chandra; Massimo Loda; Cheryl Gillett; Paul Cathcart; Ben Challacombe; Gary Cook; Declan Cahill; Aida Santa Olalla; Fidelma Cahill; Gincy George; Sarah Rudman; Mieke Van Hemelrijck
Journal:  BMC Cancer       Date:  2017-07-21       Impact factor: 4.430
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.